Management Of Excessive Sleepiness In Patients With Narcolepsy And OSA: Current Challenges And Future Prospects

References

• American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed. Darien, IL: Author; 2014.
   Google Scholar
• Jaussent I, Morin CM, Ivers H, Dauvilliers Y. Incidence, worsening and risk factors of daytime sleepiness in a population-based 5-year longitudinal study. Sci Rep. 2017;7(1):1372. doi:10.1038/s41598-017-01547-028465612
   PubMed Web of Science ®Google Scholar
• Schwartz JR, Khan A, McCall WV, Weintraub J, Tiller J. Tolerability and efficacy of armodafinil in naive patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month, open-label, flexible-dose study with an extension period. J Clin Sleep Med. 2010;6(5):450–457.20957845
   PubMed Web of Science ®Google Scholar
• Sansa G, Iranzo A, Santamaria J. Obstructive sleep apnea in narcolepsy. Sleep Med. 2010;11(1):93–95. doi:10.1016/j.sleep.2009.02.00919699146
   PubMed Web of Science ®Google Scholar
• Chapman JL, Serinel Y, Marshall NS, Grunstrin RR. Residual daytime sleepiness in obstructive sleep apnea after continuous positive airway pressure optimization: causes and management. Sleep Med Clin. 2016;11(3):353–363. doi:10.1016/j.jsmc.2016.05.00527542881
   PubMed Web of Science ®Google Scholar
• Senaratna CV, Perret JL, Lodge CJ, et al. Prevalence of obstructive sleep apnea in the general population: a systematic review. Sleep Med Rev. 2017;34:70–81. doi:10.1016/j.smrv.2016.07.00227568340
   PubMed Web of Science ®Google Scholar
• Goldbart A, Peppard P, Finn L, et al. Narcolepsy and predictors of positive MSLTs in the Wisconsin Sleep Cohort. Sleep. 2014;37(6):1043–1051. doi:10.5665/sleep.375824882899
   PubMed Web of Science ®Google Scholar
• Schuld A, Hebebrand J, Geller F, Pollmacher T. Increased body-mass index in patients with narcolepsy. Lancet. 2000;355(9211):1274–1275. doi:10.1016/S0140-6736(05)74704-8
   PubMed Web of Science ®Google Scholar
• Singh M, Drake CL, Roth T. The prevalence of multiple sleep-onset REM periods in a population-based sample. Sleep. 2006;29(7):890–895. doi:10.1093/sleep/29.7.89016895255
   PubMed Web of Science ®Google Scholar
• de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptieds with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95(1):322–327. doi:10.1073/pnas.95.1.3229419374
   PubMed Web of Science ®Google Scholar
• Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and g protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573–585. doi:10.1016/s0092-8674(00)80949-69491897
   PubMed Web of Science ®Google Scholar
• Kornum BR, Knudsen S, Ollila HM, et al. Narcolepsy. Nat Rev Dis Primers. 2017;3:16100. doi:10.1038/nrdp.2016.10028179647
   PubMed Web of Science ®Google Scholar
• Mignot E, Lin L, Rogers W, et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet. 2001;68(3):686–699. doi:10.1086/31879911179016
   PubMed Web of Science ®Google Scholar
• Heier MS, Jansson TS, Gautvik KM. Cerebrospinal fluid hypocretin 1 deficiency, overweight, and metabolic dysregulation in patients with narcolepsy. J Clin Sleep Med. 2011;7(6):653–658. doi:10.5664/jcsm.147422171205
   PubMed Web of Science ®Google Scholar
• Luca G, Haba-Rubio J, Dauvilliers Y, et al. Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study. J Sleep Res. 2013;22(5):482–495. doi:10.1111/jsr.1204423496005
   PubMed Web of Science ®Google Scholar
• Fortuyn HA, Swinkels S, Buitelaar J, et al. High prevalence of eating disorders in narcolepsy with cataplexy: a case-control study. Sleep. 2008;31(3):335–341. doi:10.1093/sleep/31.3.33518363309
   PubMed Web of Science ®Google Scholar
• van Holst RJ, van der Cruijsen L, van Mierlo P, et al. Aberrant food choices after satiation in human orexin-deficient narcolepsy type 1. Sleep. 2016;39(11):1951–1959. doi:10.5665/sleep.622227568806
   PubMed Web of Science ®Google Scholar
• He K, Kapur VK. Sleep-disordered breathing and excessive daytime sleepiness. Sleep Med Clin. 2017;12(3):369–382. doi:10.1016/j.jsmc.2017.03.01028778235
   PubMed Web of Science ®Google Scholar
• Mediano O, Barcelo A, de la Pena M, Gozal D, Agusti A, Barbe F. Daytime sleepiness and polysomnographic variables in sleep apnoea patients. Eur Respir J. 2007;30(1):110–113. doi:10.1183/09031936.0000950617360730
   PubMed Web of Science ®Google Scholar
• Garbarino S, Scoditti E, Lanteri P, Conte L, Magnavita N, Toraldo DM. Obstructive sleep apnea with our without excessive daytime sleepiness: clinical and experimental data-driven phenotyping. Front Neurol. 2018;9:505. doi:10.3389/fneur.2018.0050529997573
   PubMed Web of Science ®Google Scholar
• Veasey SC, Davis CW, Fenik P, et al. Long-term intermittent hypoxia in mice: protracted hypersomnolence with oxidative injury to sleep-wake brain regions. Sleep. 2004;27(2):194–201. doi:10.1093/sleep/27.2.19415124711
   PubMed Web of Science ®Google Scholar
• Zhu Y, Fenik P, Zhan G, et al. Selective loss of catecholaminergic wake active neurons in a murine sleep apnea model. J Neurosci. 2007;27(37):10060–10071. doi:10.1523/JNEUROSCI.0857-07.200717855620
   PubMed Web of Science ®Google Scholar
• Chervin RD, Aldrich MS. Sleep onset REM periods during multiple sleep latency tests in patients evaluated for sleep apnea. Am J Respir Crit Care Med. 2000;161(2 Pt 1):426–431. doi:10.1164/ajrccm.161.2.990507110673181
   PubMed Web of Science ®Google Scholar
• Lombardi C, Parati G, Cortelli P, et al. Daytime sleepiness and neural cardiac modulation in sleep-related breathing disorders. J Sleep Res. 2008;17(3):263–270. doi:10.1111/j.1365-2869.2008.00659.x18503513
   PubMed Web of Science ®Google Scholar
• Castiglioni P, Lombardi C, Di Rienzo M, et al. What are the causes of excessive daytime sleepiness in patients with sleep-disordered breathing? Eur Respir J. 2008;32(2):526–527. doi:10.1183/09031936.0004330818669796
   PubMed Web of Science ®Google Scholar
• Panossian LA, Veasey SC. Daytime sleepiness in obesity: mechanisms beyond obstructive sleep apnea – a review. Sleep. 2012;35(5):605–615. doi:10.5665/sleep.181222547886
   PubMed Web of Science ®Google Scholar
• Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540–545. doi:10.1093/sleep/14.6.5401798888
   PubMed Web of Science ®Google Scholar
• Johns M, Hocking B. Daytime sleepiness and sleep habits of Australian workers. Sleep. 1997;20(10):844–849. doi:10.1093/sleep/20.10.8449415943
   PubMed Web of Science ®Google Scholar
• Janssen KC, Phillipson S, O’Connor J, Johns MW. Validation of the epworth sleepiness scale for children and adolescents using rasch analysis. Sleep Med. 2017;33:30–35. doi:10.1016/j.sleep.2017.01.01428449902
   PubMed Web of Science ®Google Scholar
• Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC. Quantification of sleepiness: a new approach. Psychophysiology. 1973;10(4):431–436. doi:10.1111/j.1469-8986.1973.tb00801.x4719486
   PubMed Web of Science ®Google Scholar
• Kaida K, Takahashi M, Akerstedt T, et al. Validation of the Karolinska sleepiness scale against performance and EEG variables. Clin Neurophysiol. 2006;117(7):1574–1581. doi:10.1016/j.clinph.2006.03.01116679057
   PubMed Web of Science ®Google Scholar
• Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213. doi:10.1016/0165-1781(89)90047-42748771
   PubMed Web of Science ®Google Scholar
• Sturzenegger C, Bassetti CL. The clinical spectrum of narcolepsy with cataplexy: a reappraisal. J Sleep Res. 2004;13(4):395–406. doi:10.1111/j.1365-2869.2004.00422.x15560774
   PubMed Web of Science ®Google Scholar
• Littner MR, Kushida C, Wise M, et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep. 2005;28(1):113–121. doi:10.1093/sleep/28.1.11315700727
   PubMed Web of Science ®Google Scholar
• Kushida CA, Littner MR, Morgenthaler T, et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep. 2005;28(4):499–521. doi:10.1093/sleep/28.4.49916171294
   PubMed Web of Science ®Google Scholar
• Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2017;13(3):479–504. doi:10.5664/jcsm.650628162150
   PubMed Web of Science ®Google Scholar
• Pataka AD, Frangulyan RR, Mackay TW, Douglas NJ, Riha RL. Narcolepsy and sleep-disordered breathing. Eur J Neurol. 2012;19(5):696–702. doi:10.1111/j.1468-1331.2011.03610.x22182320
   PubMed Web of Science ®Google Scholar
• Morgenthaler TI, Kapen S, Lee-Chiong T, et al. Practice parameters for the medical therapy of obstructive sleep apnea. Sleep. 2006;29(8):1031–1035.16944671
   PubMed Web of Science ®Google Scholar
• Mayo Clinic Laboratories. ORXNA: orexin-A/hypocretin-1, spinal fluid. 2019 Available from: https://www.mayocliniclabs.com/test-catalog/Overview/604230. Accessed August 29, 2019.
   Google Scholar
• Morse AM, Sanjeev K. Narcolepsy and psychiatric disorders: comorbidities or shared pathophysiology? Med Sci (Basel). 2018;6(1):16.
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: Author; 2013.
   Google Scholar
• Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59(10):1553–1562. doi:10.1001/archneur.59.10.155312374492
   PubMed Web of Science ®Google Scholar
• Hirtz C, Vialaret J, Gabelle A, Nowak N, Dauvilliers Y, Lehmann S. From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. Sci Rep. 2016;6:25162. doi:10.1038/srep2516227165941
   PubMed Web of Science ®Google Scholar
• Ono T. Evaluation of commercial RIA and ELISA for measuring CSF orexin-A (hypocretin-1). Sleep. 2017;40(suppl1):A247. doi:10.1093/sleepj/zsx050.667
   Web of Science ®Google Scholar
• Andlauer O, Moore H, Hong S-C, et al. Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep. 2012;35(9):1247–1255F. doi:10.5665/sleep.208022942503
   PubMed Web of Science ®Google Scholar
• Capittini C, De Silvestri A, Terzaghi M, et al. Correlation between HLA-DQB1*06:02 and narcolepsy with and without cataplexy: approving a safe and sensitive genetic test in four major ethnic groups. A systematic meta-analysis. Sleep Med. 2018;52:150–157. doi:10.1016/j.sleep.2018.08.02430321823
   PubMed Web of Science ®Google Scholar
• Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30(12):1705–1711. doi:10.1093/sleep/30.12.170518246980
   PubMed Web of Science ®Google Scholar
• Rogers AE, Aldrich MS, Lin X. A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy. Sleep. 2001;24(4):385–391. doi:10.1093/sleep/24.4.38511403522
   PubMed Web of Science ®Google Scholar
• Jennum P, Ibsen R, Petersen ER, Knudsen S, Kjellberg J. Health, social, and economic consequences of narcolepsy: a controlled national study evaluating the societal effect on patients and their partners. Sleep Med. 2012;13(8):1086–1093. doi:10.1016/j.sleep.2012.06.00622841027
   PubMed Web of Science ®Google Scholar
• Bosco A, Lopez R, Barateau L, et al. Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy. Neurology. 2018;90(6):e479–e491. doi:10.1212/WNL.000000000000491129321233
   PubMed Web of Science ®Google Scholar
• Lammers GJ. Drugs used in narcolepsy and other hypersomnias. Sleep Med Clin. 2018;13(2):183–189. doi:10.1016/j.jsmc.2018.02.00929759269
   PubMed Web of Science ®Google Scholar
• Mantyh WG, Auger RR, Morgenthaler TI, Silber MH, Moore WR. Examining the frequency of stimulant misuse among patients with primary disorders of hypersomnolence: a retrospective cohort study. J Clin Sleep Med. 2016;12(5):659–662. doi:10.5664/jcsm.578826943713
   PubMed Web of Science ®Google Scholar
• Khan Z, Trotti LM. Central disorders of hypersomnolence: focus on the narcolepsies and idiopathic hypersomnia. Chest. 2015;148(1):262–273. doi:10.1378/chest.14-130426149554
   PubMed Web of Science ®Google Scholar
• Schwartz JRL. Modafinil in the treatment of excessive sleepiness. Drug Des Devel Ther. 2009;2:71–85.
   Google Scholar
• Mitler MM, Harsh J, Hirshkowitz M, Guilleminault C. Long-term efficacy and safety of modafinil (PROVIGIL((R))) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Med. 2000;1(3):231–243.10828434
   PubMed Web of Science ®Google Scholar
• Dinges DF, Weaver TE. Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP. Sleep Med. 2003;4(5):393–402.14592280
   PubMed Web of Science ®Google Scholar
• Kallweit U, Bassetti CL. Pharmacological management of narcolepsy with and without cataplexy. Expert Opin Pharmacother. 2017;18(8):809–817. doi:10.1080/14656566.2017.132387728443381
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Hellriegel ET, Robertson P Jr. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. Clin Drug Investig. 2009;29(9):613–623. doi:10.2165/11315280-000000000-00000
   PubMed Web of Science ®Google Scholar
• Schweitzer PK, Rosenberg R, Zammit GK, et al. Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3): a randomized controlled trial. Am J Respir Crit Care Med. 2019;199(11):1421–1431.30521757
   PubMed Web of Science ®Google Scholar
• Thorpy MJ, Shapiro C, Mayer G, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85(3):359–370. doi:10.1002/ana.2542330694576
   PubMed Web of Science ®Google Scholar
• Mitler MM, Hajdukovic R, Erman M, Koziol JA. Narcolepsy. J Clin Neurophysiol. 1990;7(1):93–118.1968069
   PubMed Web of Science ®Google Scholar
• Takenoshita S, Nishino S. Pharmacologic management of excessive daytime sleepiness. Sleep Med Clin. 2017;12(3):461–478. doi:10.1016/j.jsmc.2017.03.01928778242
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Bassetti C, Lammers GJ, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12(11):1068–1075. doi:10.1016/S1474-4422(13)70225-424107292
   PubMed Web of Science ®Google Scholar
• Alshaikh MK, Tricco AC, Tashkandi M, Mamdani M, Straus SE, BaHammam AS. Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis. J Clin Sleep Med. 2012;8(4):451–458. doi:10.5664/jcsm.204822893778
   PubMed Web of Science ®Google Scholar
• Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006;29(7):939–946. doi:10.1093/sleep/29.7.93916895262
   PubMed Web of Science ®Google Scholar
• Avadel. REST-ON. 2018; http://clinicaltrial.avadel.com/hcp.html Accessed 912, 2019.
   Google Scholar
• Xyrem® International Study Group. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J Toxicol Clin Toxicol. 2003;41(2):131–135.12733850
   PubMed Web of Science ®Google Scholar
• Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365(20):1896–1904. doi:10.1056/NEJMoa111021222043968
   PubMed Web of Science ®Google Scholar
• Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. Jama. 2011;306(24):2673–2683. doi:10.1001/jama.2011.183022161946
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA drug safety communication: safety review update of medications used to treat attention-deficit/hyperactivity disorder (ADHD) in children and young adults. 2018; http://www.fda.gov/Drugs/DrugSafety/ucm277770.htm Accessed 912, 2019.
   Google Scholar
• American Academy of Pediatrics/American Heart. Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008. J Dev Behav Pediatr. 2008;29(4):335.18698199
   PubMedGoogle Scholar
• Patil SP, Ayappa IA, Caples SM, Kimoff J, Patel SR, Harrod CG. Treatment of adult obstructive sleep apnea with positive airway pressure: an American academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2019;15(2):335–343. doi:10.5664/jcsm.764030736887
   PubMed Web of Science ®Google Scholar
• Weaver TE, Maislin G, Dinges DF, et al. Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. Sleep. 2007;30(6):711–719. doi:10.1093/sleep/30.6.71117580592
   PubMed Web of Science ®Google Scholar
• Babiker MO, Prasad M. Narcolepsy in children: a diagnostic and management approach. Pediatr Neurol. 2015;52(6):557–565. doi:10.1016/j.pediatrneurol.2015.02.02025838042
   PubMed Web of Science ®Google Scholar
• Plazzi G, Ruoff C, Lecendreux M, et al. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomized-withdrawl, multicenter study and open label investigation. Lancet Child Adolesc Health. 2018;2(7):483–494. doi:10.1016/S2352-4642(18)30133-030169321
   PubMedGoogle Scholar
• Biyani S, Cunningham TD, Baldassari CM. Adenotonsillectomy outcomes in children with sleep apnea and narcolepsy. Int J Pediatr Otorhinolaryngol. 2017;100:62–65. doi:10.1016/j.ijporl.2017.06.01828802388
   PubMed Web of Science ®Google Scholar
• Nepovimova E, Janockova J, Misik J, et al. Orexin supplementation in narcolepsy treatment: a review. Med Res Rev. 2019;39(3):961–975. doi:10.1002/med.2155030426515
   PubMed Web of Science ®Google Scholar
• Irukayama-Tomobe Y, Ogawa Y, Tominaga H, et al. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. Proc Natl Acad Sci USA. 2017;114(22):5731–5736. doi:10.1073/pnas.170049911428507129
   PubMed Web of Science ®Google Scholar
• Kimura H, Ishikawa T, Yukitake H, Suzuki M. An orexin 2 receptor-selective agonist, TAK-925, ameliorates narcolepsy-like symptoms and obesity in orexin/ataxin-3 transgenic mice. Sleep. 2019;42(suppl1):A23. doi:10.1093/sleep/zsz067.054
   Google Scholar
• Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US modafinil in narcolepsy multicenter study group. Ann Neurol. 1998;43(1):88–97. doi:10.1002/ana.4104301159450772
   PubMedGoogle Scholar
• Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin. 2006;22(4):761–774. doi:10.1185/030079906X10005016684437
   PubMed Web of Science ®Google Scholar
• Mitler MM, Hajdukovic R, Erman MK. Treatment of narcolepsy with methamphetamine. Sleep. 1993;16(4):306–317.8341891
   PubMed Web of Science ®Google Scholar
• Xyrem® International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med. 2005;1(4):391–397.17564408
   PubMed Web of Science ®Google Scholar